A Phase I-II Trial of Daratumumab for the Treatment of Patients With AL Amyloidosis
Phase of Trial: Phase I/II
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Daratumumab (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- 12 Dec 2017 Preliminary results (n=8; As of July 23, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 28 Mar 2017 Status changed from not yet recruiting to recruiting.
- 02 Sep 2016 Planned initiation date changed from 1 Jul 2016 to 1 Oct 2016.